Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Upgrades AnaptysBio to Buy

Guggenheim Upgrades AnaptysBio to Buy

Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.

byBenzinga Newsdesk

November 1, 2022

1 minute read

Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy.

Squarespace Q3 EPS $0.07 Misses $0.11 Estimate, Sales $217.70M Beat $215.66M Estimate

By Benzinga Newsdesk

November 8, 7:06 AM

Squarespace (NYSE:SQSP) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.11 by 36.36 percent. This is a 250 percent increase over earnings of $0.02 per share from the same

SQSP

News

Sagaliam Acquisition Corp. Confirms Funding And Extension Of Deadline To Complete Initial Business Combination To January 23, 2023

By Benzinga Newsdesk

December 23, 12:26 PM

Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it was exercising its

SAGA

Bank of Hawaii Q3 EPS $1.28 Misses $1.43 Estimate, Sales $172.31M Miss $182.64M Estimate

By Benzinga Newsdesk

October 24, 6:49 AM

Bank of Hawaii (NYSE:BOH) reported quarterly earnings of $1.28 per share which missed the analyst consensus estimate of $1.43 by 10.49 percent. This is a 15.79 percent decrease over earnings of $1.52 per share from the

BOH